

From the INTERNATIONAL BUREAU


PCT

NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
PRELIMINARY REPORT ON PATENTABILITY
(CHAPTER I OF THE PATENT COOPERATION
TREATY)

(PCT Rule 44bis.1(c))

To:

G.E. EHRLICH (1995) LTD.
11 Menachem Begin Street
52521 Ramat Gan
ISRAËL

**IMPORTANT NOTICE**

Date of mailing (day/month/year)

29 April 2010 (29.04.2010)

Applicant's or agent's file reference

43186

International application No.

PCT/IL2008/000576

International filing date (day/month/year)

30 April 2008 (30.04.2008)

Priority date (day/month/year)

30 April 2007 (30.04.2007)

Applicant

PROTALIX LTD. et al

The International Bureau transmits herewith a copy of the international preliminary report on patentability (Chapter I of the Patent Cooperation Treaty)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 338 82 70

Authorized officer

Simin Baharlou

e-mail: pt09.pct@wipo.int

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference 43186	FOR FURTHER ACTION	See item 4 below
International application No. PCT/IL2008/000576	International filing date (<i>day/month/year</i>) 30 April 2008 (30.04.2008)	Priority date (<i>day/month/year</i>) 30 April 2007 (30.04.2007)
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237		
Applicant PROTALIX LTD.		

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).																								
2.	<p>This REPORT consists of a total of 9 sheets, including this cover sheet.</p> <p>In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.</p>																								
3.	<p>This report contains indications relating to the following items:</p> <table style="width: 100%; border: none;"> <tr> <td style="width: 10%; text-align: center;"><input checked="" type="checkbox"/></td> <td style="width: 30%;">Box No. I</td> <td style="width: 60%;">Basis of the report</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td>Box No. II</td> <td>Priority</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td>Box No. III</td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td>Box No. IV</td> <td>Lack of unity of invention</td> </tr> <tr> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Box No. V</td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td>Box No. VI</td> <td>Certain documents cited</td> </tr> <tr> <td style="text-align: center;"><input type="checkbox"/></td> <td>Box No. VII</td> <td>Certain defects in the international application</td> </tr> <tr> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td>Box No. VIII</td> <td>Certain observations on the international application</td> </tr> </table>	<input checked="" type="checkbox"/>	Box No. I	Basis of the report	<input type="checkbox"/>	Box No. II	Priority	<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	<input type="checkbox"/>	Box No. IV	Lack of unity of invention	<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	<input type="checkbox"/>	Box No. VI	Certain documents cited	<input type="checkbox"/>	Box No. VII	Certain defects in the international application	<input checked="" type="checkbox"/>	Box No. VIII	Certain observations on the international application
<input checked="" type="checkbox"/>	Box No. I	Basis of the report																							
<input type="checkbox"/>	Box No. II	Priority																							
<input type="checkbox"/>	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
<input type="checkbox"/>	Box No. IV	Lack of unity of invention																							
<input checked="" type="checkbox"/>	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
<input type="checkbox"/>	Box No. VI	Certain documents cited																							
<input type="checkbox"/>	Box No. VII	Certain defects in the international application																							
<input checked="" type="checkbox"/>	Box No. VIII	Certain observations on the international application																							
4.	The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).																								

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Date of issuance of this report 20 April 2010 (20.04.2010)
Facsimile No. +41 22 338 82 70	Authorized officer <div style="text-align: center; font-weight: bold; font-size: 1.2em;">Simin Baharlou</div> e-mail: pt09.pct@wipo.int

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To: **G.E. EHRLICH (1995) LTD.**
11 MENACHEM BEGIN STREET
52521 RAMAT GAN
ISRAEL

PCT

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing
(day/month/year)

09 APR 2010

Applicant's or agent's file reference
43186

FOR FURTHER ACTION

See paragraph 2 below

International application No.

PCT/IL 08/00576

International filing date (day/month/year)

30 April 2008 (30.04.2008)

Priority date (day/month/year)

30 April 2007 (30.04.2007)

International Patent Classification (IPC) or both national classification and IPC

IPC(8) - C07H 21/04, C07K 14/00 (2010.01)

USPC - 536/23.5, 530/350, 435/419, 45/69.1

Applicant **PROTALIX LTD.**

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☒ Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Date of completion of this opinion

17 March 2010 (17.03.2010)

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/IL 08/00576

Box No. I Basis of this opinion

1. With regard to the **language**, this opinion has been established on the basis of:
☒ the international application in the language in which it was filed.
☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2. ☐ This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43*bis*.1(a)).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing filed or furnished:
 - a. (means)
☐ on paper
☒ in electronic form
 - b. (time)
☐ in the international application as filed
☒ together with the international application in electronic form
☐ subsequently to this Authority for the purposes of search
4. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/IL 08/00576

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	3-7, 9, 16, 19, 21, 24, 31, 32, 34-36, 39, 41, 45-51, 56, 57	YES
	Claims	SEE CONTINUATION SHEET.	NO
Inventive step (IS)	Claims	6, 7, 36, 51	YES
	Claims	1-5, 8-35, 37-50, 52-60	NO
Industrial applicability (IA)	Claims	1-60	YES
	Claims	NONE	NO

2. Citations and explanations:

Claims 1, 2, 8, 10-15, 17, 18, 20, 22, 23, 25-30, 33, 37, 38, 40, 42-44, 52-55 and 58-60 lack novelty under PCT Article 33(2) as being anticipated by US 2006/0204487 A1 to Shaatiel et al. (hereinafter 'Shaatiel '487').

Regarding claim 1, Shaatiel '487 teaches an isolated nucleic acid sequence (para [0067], [0077], SEQ ID NO: 8) encoding a human (para [0038], [0149]) lysosomal protein (para [0067]) being contiguously linked to a C-terminal vacuolar targeting signal (para [0028], [0067]), and an N-terminal endoplasmic reticulum signal peptide (para [0023], [0028], [0128]), wherein said human (para [0038], [0149]) lysosomal protein is a human alpha-galactosidase (para [0038], [0046]).

Regarding claim 2, Shaatiel '487 teaches an isolated nucleic acid sequence (para [0067], [0077], SEQ ID NO: 8) encoding a human lysosomal protein (para [0067]) being contiguously linked to a C-terminal (para [0028]) endoplasmic reticulum retention signal (para [0127], [0141]) and an N-terminal endoplasmic reticulum signal peptide (para [0023], [0028], [0128]), wherein said human (para [0038], [0149]) lysosomal protein is a human alpha-galactosidase (para [0038], [0046]).

Regarding claim 8, Shaatiel '487 teaches the isolated nucleic acid construct of claim 1, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is human alpha-galactosidase (para [0038], [0046]).

Regarding claim 10, Shaatiel '487 teaches a nucleic acid construct (para [0133], [0141]) capable of expression in a plant cell (para [0020]) comprising the isolated nucleic acid (para [0067], [0077], SEQ ID NO: 8) of claim 1.

Regarding claim 11, Shaatiel '487 teaches a nucleic acid construct (para [0133], [0141]) capable of expression in a plant cell (para [0020]) comprising the isolated nucleic acid (para [0067], [0077], SEQ ID NO: 8) of claim 2.

Regarding claim 12, Shaatiel '487 teaches a cell (para [0033], [0139], root cells) comprising the nucleic acid construct (para [0133], [0141]) of claim 10.

Regarding claim 13, Shaatiel '487 teaches a cell (para [0033], [0139], root cells) comprising the nucleic acid construct (para [0133], [0141]) of claim 11.

Regarding claim 14, Shaatiel '487 teaches the cell of claim 13, recombinantly producing (para [0030]) said human (para [0038], [0149]) lysosomal enzyme (para [0065], [0067]).

Regarding claim 15, Shaatiel '487 teaches the cell of claim 13, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is recombinantly produced (para [0030]) so as to have at least one xylose (para [0024], [0310]) and at least one exposed mannose residue (para [0037], [0041]).

Regarding claim 17, Shaatiel '487 teaches the cell of claim 13, wherein said cell is a plant cell (para [0139], carrot cell).

Regarding claim 18, Shaatiel '487 teaches the cell of claim 17, wherein said plant cell is a plant root cell (para [0033], [0139]) consisting of a carrot cell (para [0139]).

Regarding claim 20, Shaatiel '487 teaches the cell of claim 13, wherein said cell is an *Agrobacterium tumefaciens* cell (para [0070]).

Regarding claim 22, Shaatiel '487 teaches a human (para [0038], [0149]) lysosomal protein (para [0067]) comprising at least one exposed mannose residue (para [0037], [0041]) and at least one fucose residue (para [0024], [0310]) having an alpha (1-3) glycosidic bond (para [0308], [0310]).

Regarding claim 23, Shaatiel '487 teaches the human lysosomal protein of claim 22, further comprising at least one xylose residue (para [0024], [0310]).

Regarding claim 25, Shaatiel '487 teaches the human lysosomal protein of claim 22, wherein said lysosomal enzyme (para [0065], [0067]) is a glucocerebrosidase (para [0021], [0076]).

SEE CONTINUATION SHEET.

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/IL 08/00576

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
Claim 55 as written is dependent upon claim 54. However, the claim lacks an antecedent for the vacuolar targeting signal. Therefore, for purposes of the opinion, claim 54 is deemed to depend on claim 52.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/IL 08/00576

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:
Box V, No 1

NOVELTY (NO) – 1, 2, 8, 10-15, 17, 18, 20, 22, 23, 25-30, 33, 37, 38, 40, 42-44, 52-55, 58-60

Box V, No 2

Regarding claim 26, Shaatiel '487 teaches the human lysosomal protein of claim 22, wherein said human (para [0038], [0149]) lysosomal enzyme (para [0065], [0067]) is human alpha-galactosidase (para [0038], [0046]).

Regarding claim 27, Shaatiel '487 teaches the human lysosomal protein of claim 22, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is contiguously linked to a C-terminal vacuolar targeting signal (para [0028], [0067]).

Regarding claim 28, Shaatiel '487 teaches the human lysosomal protein of claim 22, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is contiguously linked to a C-terminal vacuolar targeting signal (para [0028], [0067]) and an N-terminal endoplasmic reticulum signal peptide (para [0023], [0028], [0128]).

Regarding claim 29, Shaatiel '487 teaches the human lysosomal protein of claim 22, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is contiguously linked to a C-terminal (para [0028]) endoplasmic reticulum retention signal (para [0127], [0141]) and an N-terminal endoplasmic reticulum signal peptide (para [0023], [0028], [0128]).

Regarding claim 30, Shaatiel '487 teaches the human lysosomal protein of claim 27, wherein said vacuolar targeting signal (para [0028], [0067]) is a basic tobacco chitinase A gene vacuolar targeting signal (para [0028], [0035], [0142]).

Regarding claim 33, Shaatiel '487 teaches the human lysosomal protein of claim 25, wherein said human glucocerebrosidase (para [0021], [0076]) comprises an amino acid sequence as set forth in SEQ ID NO: 8 (para [0077], claim 23, SEQ ID NO: 8).

Regarding claim 37, Shaatiel '487 teaches the human lysosomal protein of claim 22, wherein said lysosomal protein (para [0067]) has a biological activity (para [0020], enzymatically active).

Regarding claim 38, Shaatiel '487 teaches the human lysosomal protein of claim 37, wherein said biological activity is uptake into macrophages (para [0234], [0235]).

Regarding claim 40, Shaatiel '487 teaches the human lysosomal protein of claim 37, wherein said biological activity is enzymatic activity (para [0020]).

Regarding claim 42, Shaatiel '487 teaches a pharmaceutical composition (para [0063]) comprising the human lysosomal protein of claim 22 and a pharmaceutically acceptable carrier (para [0063]).

Regarding claim 43, Shaatiel '487 teaches a plant cell preparation (para [0029], [0033], [0139]) comprising a human (para [0038], [0149]) lysosomal protein (para [0067]) comprising at least one exposed mannose residue (para [0037], [0041]) and at least one fucose residue (para [0024], [0310]) having an alpha (1-3) glycosidic bond (para [0308], [0310]).

Regarding claim 44, Shaatiel '487 teaches the plant cell preparation of claim 43, further comprising at least one xylose residue (para [0024], [0310]).

Regarding claim 52, Shaatiel '487 teaches the plant cell preparation of claim 43, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is contiguously linked to a C-terminal vacuolar targeting signal (para [0028], [0067]).

Regarding claim 53, Shaatiel '487 teaches the plant cell preparation of claim 43, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is contiguously linked to a C-terminal vacuolar targeting signal (para [0028], [0067]) and an N-terminal endoplasmic reticulum signal peptide (para [0023], [0028], [0128]).

Regarding claim 54, Shaatiel '487 teaches the plant cell preparation of claim 43, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is contiguously linked to a C-terminal (para [0028]) endoplasmic reticulum retention signal (para [0127], [0141]) and an N-terminal endoplasmic reticulum signal peptide (para [0023], [0028], [0128]).

Regarding claim 55, Shaatiel '487 teaches the plant cell preparation of claim 52, wherein said vacuolar targeting signal (para [0028], [0067]) is a basic tobacco chitinase A gene vacuolar targeting signal (para [0028], [0035], [0142]).

Regarding claim 58, Shaatiel '487 teaches the plant cell preparation of claim 43, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) having at least one exposed mannose residue (para [0037], [0041]) comprises a dominant fraction (para [0248], predominantly mannose glycans) of said lysosomal protein (para [0001], [0018], protein with high mannose levels), as measured by linkage analysis (para [0245], [0306]).

Regarding claim 59, Shaatiel '487 teaches pharmaceutical composition (para [0063]) comprising the plant cell preparation of claim 43 and a pharmaceutically acceptable carrier (para [0063]).

SEE CONTINUATION SHEET.

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:
Box V, Supplemental Page 1

Regarding claim 60, Shaatiel '487 teaches the use of the biologically active lysosomal enzyme of claim 37 for the manufacture of a medicament (para [0065], [0106]) for treating lysosomal storage disease (para [0020], [0064], Gaucher's disease).

Claims 16, 21, 24, 41, 45-47 and 49 lack an inventive step under PCT Article 33(3) as being obvious over Shaatiel '487.

Regarding claim 16, Shaatiel '487 teaches the cell of claim 13, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) is recombinantly produced (para [0030]) so as to have at least one core xylose (para [0024], [0310]) and at least one core alpha-(1,3) fucose (para [0308], [0310]). Although Shaatiel '487 does not specifically teach that the core xylose is linked in an alpha (1,2) glycosidic linkage, it would have been obvious to one of ordinary skill in the art that the xylose would be linked to the other sugars in an alpha (1,2) linkage because of the well known commonality of glycosylation enzymes systems in plant tissue (para [0139]) making alpha-(1,2) glycosidic linkages with xylose.

Regarding claim 21, Shaatiel '487 teaches the cell of claim 13, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) has at least one core xylose (para [0024], [0310]) and at least one core alpha-(1,3) fucose (para [0308], [0310]). As above, although Shaatiel '487 does not specifically teach that the core xylose is linked in an alpha (1,2) glycosidic linkage, it would have been obvious to one of ordinary skill in the art that the xylose would be linked to the other sugars in an alpha (1,2) linkage because of the well known commonality of glycosylation enzymes systems in plant tissue (para [0139]) making alpha-(1,2) glycosidic linkages with xylose.

Regarding claim 24, Shaatiel '487 teaches the human lysosomal protein of claim 23, wherein said xylose residue (para [0024]) is a core xylose residue (para [0024], [0310]). As above, although Shaatiel '487 does not specifically teach that the core xylose is linked in an alpha (1,2) glycosidic linkage, it would have been obvious to one of ordinary skill in the art that the xylose would be linked to the other sugars in an alpha (1,2) linkage because of the well known commonality of glycosylation enzymes systems in plant tissue (para [0139]) making alpha-(1,2) glycosidic linkages with xylose.

Regarding claim 41, Shaatiel '487 teaches the human lysosomal protein of claim 37, having an increased affinity (para [0049], increased affinity for target cells) for said macrophages (para [0234], [0235], promotes macrophage uptake), in comparison with the corresponding affinity of a naturally occurring lysosomal protein to other target cells (para [0049]). Although Shaatiel '487 does not specifically teach that the comparative affinity of the human lysosomal protein as taught by Shaatiel '487 is greater specifically for macrophages, it would have been obvious to one of ordinary skill in the art that enhanced macrophage uptake as taught by Shaatiel '487 in macrophages (para [0234], [0235]) implies a greater binding affinity of the lysosomal protein for macrophages than native lysosomal protein would have been expected to exhibit in view of the increased capacity for of these proteins to their target cells in general (para [0049]).

Regarding claim 45, Shaatiel '487 teaches the plant cell preparation of claim 44, wherein said xylose residue (para [0024]) is a core xylose residue (para [0024], [0310]). As above, although Shaatiel '487 does not specifically teach that the core xylose is linked in an alpha (1,2) glycosidic linkage, it would have been obvious to one of ordinary skill in the art that the xylose would be linked to the other sugars in an alpha (1,2) linkage because of the well known commonality of glycosylation enzymes systems in plant tissue (para [0139]) making alpha-(1,2) glycosidic linkages with xylose.

Regarding claim 46, Shaatiel '487 teaches the plant cell preparation of claim 45, wherein said lysosomal protein (para [0067]) is a human glucocerebrosidase (para [0021], [0076]).

Regarding claim 47, Shaatiel '487 teaches the plant cell preparation of claim 46, wherein said human (para [0038], [0149]) lysosomal protein (para [0067]) comprises an amino acid sequence as set forth in SEQ ID NO: 8 (para [0077], claim 23, SEQ ID NO: 8).

Regarding claim 49, Shaatiel '487 teaches the plant cell preparation of claim 45, wherein said lysosomal protein (para [0067]) is a human (para [0038], [0149]) alpha-galactosidase (para [0038], [0046]).

Claims 3, 9, 35 and 50 lack an inventive step under PCT Article 33(3) as being obvious over Shaatiel '487 in view of US 2003/0077806 A1 to Selden et al. (hereinafter 'Selden '806').

Regarding claim 3, Shaatiel '487 teaches the isolated nucleic acid of claims 1 and 2, including a human (para [0038], [0149]) alpha-galactosidase (para [0038], [0046]) but does not teach that the alpha-galactosidase is the sequence in SEQ ID NO: 24. Selden '806 teaches an alpha-galactosidase comprising the sequence of SEQ ID NO: 24 (para [0014], Fig 6, SEQ ID NO: 4). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Selden '806 to utilize an isolated nucleic acid of a human alpha galactosidase of SEQ ID NO: 24, because the sequence of the nucleic acid of SEQ ID NO:4 as taught by Selden '806 would encode the exact alpha-galactosidase of Shaatiel '487 based on sequence identity.

Regarding claim 9, Shaatiel '487 teaches the isolated nucleic acid construct of claim 1, including a human (para [0038], [0149]) lysosomal protein (para [0067]) but does not teach that the human lysosomal protein is the sequence in SEQ ID NO: 24. Selden '806 teaches an alpha-galactosidase, a human lysosomal protein, comprising the sequence of SEQ ID NO: 24 (para [0014], Fig 6, SEQ ID NO: 4). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Selden '806 to utilize an isolated nucleic acid of a human lysosomal protein of SEQ ID NO: 24, because the sequence of the nucleic acid of SEQ ID NO:4 as taught by Selden '806 would encode the exact human lysosomal protein of Shaatiel '487 based on sequence identity.

SEE CONTINUATION SHEET.

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:
Box V, Supplemental Page 2

Regarding claim 35, Shaatiel '487 teaches the human lysosomal protein of claim 26, including a human glucocerebrosidase (para [0021], [0076]) but does not teach that the human cerbrosidase is the sequence in SEQ ID NO: 24. Selden '806 teaches a human cerbrosidase (para [0058]), comprising the sequence of SEQ ID NO: 24 (para [0014], [Fig 6, SEQ ID NO: 4]). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Selden '806 to utilize an isolated nucleic acid of a human cerebrosidase of SEQ ID NO: 24, because the sequence of the nucleic acid of SEQ ID NO:4 as taught by Selden '806 would encode the exact human cerbrosidase of Shaatiel '487 based on sequence identity.

Regarding claim 50, Shaatiel '487 teaches the plant cell preparation of claim 49, including a human glucocerebrosidase (para [0021], [0076]) but does not teach that the human cerbrosidase is the sequence in SEQ ID NO: 24. Selden '806 as above teaches a human cerbrosidase (para [0058]), comprising the sequence of SEQ ID NO: 24 (para [0014], [Fig 6, SEQ ID NO: 4]). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Selden '806 to utilize an isolated nucleic acid of a human cerebrosidase of SEQ ID NO: 24, because the sequence of the nucleic acid of SEQ ID NO:4 as taught by Selden '806 would encode the exact human cerbrosidase of Shaatiel '487 based on sequence identity.

Claims 4, 31, 32, 34, 48, 56 and 57 lack an inventive step under PCT Article 33(3) as being obvious over Shaatiel '487 in view of US 2005/0032211 A1 to Shaatiel (hereinafter 'Shaatiel '211').

Regarding claim 4, Shaatiel '487 teaches the isolated nucleic acid construct of claim 1, but does not specifically teach that said vacuolar targeting signal (para [0028], [0067]) is SEQ ID NO: 4. Shaatiel '211 teaches a vacuolar targeting signal (para [0221]) comprising the sequence of SEQ ID NO: 4 (SEQ ID NO: 4). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a vacuolar targeting signal comprising SEQ ID NO: 4 because the sequence taught by Shaatiel '211 (SEQ ID NO:4) is identical to the vacuolar targeting signal of SEQ ID NO: 4.

Regarding claim 31, Shaatiel '487 teaches the human lysosomal protein of claim 30, but does not specifically teach that said vacuolar targeting signal (para [0028], [0067]) is SEQ ID NO: 2. Shaatiel '211 teaches a vacuolar targeting signal (para [0221]) comprising the sequence of SEQ ID NO: 2 (para [0222], SEQ ID NO: 2). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a vacuolar targeting signal comprising SEQ ID NO: 2 because the sequence taught by Shaatiel '211 (para [0222], SEQ ID NO:2) is identical to the vacuolar targeting signal of SEQ ID NO: 2.

Regarding claim 32, Shaatiel '487 teaches the human lysosomal protein of claim 28, but does not specifically teach that said endoplasmic reticulum signal peptide (para [0023], [0028], [0128]) is SEQ ID NO: 1 or SEQ ID NO: 16. Shaatiel '211 teaches an endoplasmic reticulum signal peptide (para [0222]) comprising the sequence of SEQ ID NO: 1 (para [0222], SEQ ID NO: 1). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a vacuolar targeting signal comprising SEQ ID NO: 1 because the sequence taught by Shaatiel '211 (para [0222], SEQ ID NO:1) is identical to the endoplasmic reticulum signal peptide of SEQ ID NO: 1.

Regarding claim 34, Shaatiel '487 teaches the human lysosomal protein of claim 25, but does specifically teach that the human (para [0038], [0149]) lysosomal protein (para [0067]) comprises an amino acid sequence as set forth in SEQ ID NO: 15. Shaatiel '211 teaches a lysosomal protein (para [0028]) comprising the sequence of SEQ ID NO: 15 (SEQ ID NO: 14). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a human lysosomal protein comprising SEQ ID NO: 15 because the sequence taught by Shaatiel '211 (SEQ ID NO:14) is identical to the human lysosomal protein of SEQ ID NO: 15.

Regarding claim 48, Shaatiel '487 teaches the plant cell preparation of claim 46, but does specifically teach that the human (para [0038], [0149]) lysosomal protein (para [0067]) comprises an amino acid sequence as set forth in SEQ ID NO: 15. Shaatiel '211 as above teaches a lysosomal protein (para [0028]) comprising the sequence of SEQ ID NO: 15 (SEQ ID NO: 14). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a human lysosomal protein comprising SEQ ID NO: 15 because the sequence taught by Shaatiel '211 (SEQ ID NO:14) is identical to the human lysosomal protein of SEQ ID NO: 15.

Regarding claim 56, Shaatiel '487 teaches the plant cell preparation of claim 55, but does not specifically teach that said vacuolar targeting signal (para [0028], [0067]) is SEQ ID NO: 2. Shaatiel '211 as above teaches a vacuolar targeting signal (para [0221]) comprising the sequence of SEQ ID NO: 2 (para [0222], SEQ ID NO: 2). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a vacuolar targeting signal comprising SEQ ID NO: 2 because the sequence taught by Shaatiel '211 (para [0222], SEQ ID NO:2) is identical to the vacuolar targeting signal of SEQ ID NO: 2.

Regarding claim 57, Shaatiel '487 teaches the plant cell preparation of claim 55, but does not specifically teach that said endoplasmic reticulum signal peptide (para [0023], [0028], [0128]) is SEQ ID NO: 1 or SEQ ID NO: 16. Shaatiel '211 as above teaches an endoplasmic reticulum signal peptide (para [0222]) comprising the sequence of SEQ ID NO: 1 (para [0222], SEQ ID NO: 1). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Shaatiel '211 to provide a vacuolar targeting signal comprising SEQ ID NO: 1 because the sequence taught by Shaatiel '211 (para [0222], SEQ ID NO:1) is identical to the endoplasmic reticulum signal peptide of SEQ ID NO: 1.

SEE CONTINUATION SHEET.

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/IL 08/00576

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of:
Box V, Supplemental Page 3

Claims 5 and 19 lack an inventive step under PCT Article 33(3) as being obvious over Shaatiel '487 in view of WO 2007/005882 A2 to Weissinger et al. (hereinafter "Weissinger").

Regarding claim 5, Shaatiel '487 teaches the isolated nucleic acid construct of claim 2 but does not specifically teach that the endoplasmic reticulum retention signal (para [0023], [0028], [0128]) is SEQ ID NO:23 (KDEL). Weissinger teaches SEQ ID NO:23 (KDEL) for endoplasmic reticulum targeting (pg 5, ln 21-23, Fig 5, SEQ ID NO:4) for expressing foreign genes in plants (pg 1, ln 12-14). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Weissinger to use a KDEL peptide (SEQ ID NO:23) as an endoplasmic reticulum retention signal, because the peptide KDEL functions in the same capacity for endoplasmic reticulum retention as taught by Weissinger.

Regarding claim 19, Shaatiel '487 teaches the cell of claim 17 but does not specifically teach that the plant cell (para [0139]) is a tobacco cell. Weissinger teaches expression of foreign genes in plants (pg 1, ln 12-14) wherein the plants comprise tobacco cells (pg 4, ln 10-15). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and Weissinger to utilize tobacco cells for the expression of polynucleotides encoding lysosomal proteins, because the use of tobacco cells for the expression of similar heterologous genes as taught by Weissinger makes them an exemplary candidate for lysosomal protein production.

Claim 39 lacks an inventive step under PCT Article 33(3) as being obvious over Shaatiel '487 in view of US 2005/0281805 A1 to LeBowitz et al. (hereinafter "LeBowitz").

Regarding claim 39, Shaatiel '487 teaches the human lysosomal protein of claim 37 but does not specifically teach that the said biological activity (of the lysosomal protein) (para [0067]) is uptake into fibroblasts. LeBowitz teaches uptake of modified alpha galactosidase for treatment of Fabry's disease (para [0160], [0199]) in fibroblasts (para [0049], [0166], [0167], [0175]). It would have been obvious to one of ordinary skill in the art to combine the teachings of Shaatiel '487 and LeBowitz to test for fibroblast uptake enhancement of lysosomal proteins such as alpha-galactosidase based on the teaching LeBowitz which relates fibroblast uptake with treatment of Fabry's disease, a genetic disease resulting from alpha galactosidase deficiency.

Claims 6, 7, 36 and 51 meet the criteria set out in PCT Article 33(2)-33(3) because the prior art does not teach or clearly suggest the claimed subject matter.

Regarding claim 6, Shaatiel '487 teaches the isolated nucleic acid construct of claim 2, but does not specifically teach that the construct comprises SEQ ID NO:19. WO 2008/132743 A2 to Shaatiel et al. (hereinafter "Shaatiel '743") teaches SEQ ID NO:19 (SEQ ID NO: 19), but since Shaatiel '487 was published after the priority date of the present claim is not prior art; the prior art neither teaches nor suggests the nucleic acid construct comprising SEQ ID NO: 19.

Regarding claim 7, Shaatiel '487 teaches the isolated nucleic acid construct of claim 2, but does not specifically teach that the construct comprises SEQ ID NO:17. Shaatiel '743 teaches SEQ ID NO:17 (SEQ ID NO: 17), but since Shaatiel '487 was published after the priority date of the present claim is not prior art; the prior art neither teaches nor suggests the nucleic acid construct comprising SEQ ID NO: 17.

Regarding claim 36, Shaatiel '487 teaches the human lysosomal protein of claim 26 but does not specifically teach that the human (para [0038], [0149]) lysosomal protein (para [0067]) comprises an amino acid sequence as set forth in SEQ ID NOS: 18 or 20. US 6,083,725 A to Selden et al. (hereinafter "Selden '725") teaches a sequence having 93% homology to SEQ ID NO: 18. US 2002/0088024 A1 to Garger et al. (hereinafter "Garger") teaches a sequence having 92% homology to SEQ ID NO: 20. However, since neither Selden '725 nor Garger teaches the specific sequence of SEQ ID NO: 20 or SEQ ID NO: 18, the prior art neither teaches nor suggests the lysosomal protein comprising SEQ ID NOS: 18 or 20.

Regarding claim 51, Shaatiel '487 teaches the plant cell preparation of claim 49, but as above does not specifically teach that the human (para [0038], [0149]) lysosomal protein (para [0067]) comprises an amino acid sequence as set forth in SEQ ID NOS: 18 or 20. Selden '725 as above teaches a sequence having 93% homology to SEQ ID NO: 18. Garger as above teaches a sequence having 92% homology to SEQ ID NO: 20. However, since neither Selden '725 nor Garger teaches the specific sequence of SEQ ID NO: 20 or SEQ ID NO: 18, the prior art neither teaches nor suggests the lysosomal protein comprising SEQ ID NOS: 18 or 20.

Claims 1-60 have industrial applicability as defined by PCT Article 33(4) because the subject matter can be made or used in industry.

